BAYER AG
- Country
- 🇩🇪Germany
- Ownership
- Public
- Established
- 1863-08-01
- Employees
- 99.7K
- Market Cap
- $30.1B
- Website
- http://www.bayer.com
A Study to Learn About How Well BAY3283142 Works and Its Safety in Participants With Chronic Kidney Disease
- First Posted Date
- 2024-07-26
- Last Posted Date
- 2024-12-17
- Lead Sponsor
- Bayer
- Target Recruit Count
- 700
- Registration Number
- NCT06522997
- Locations
- 🇮🇹
Istituti Clinici Scientifici Maugeri S.p.A._Pavia - Nefrologia, Pavia, Italy
🇺🇸Nephrology Consultants, LLC, Huntsville, Alabama, United States
🇺🇸California Institute of Renal Research - Chula Vista, Chula Vista, California, United States
A Study to Learn About Whether BAYH006689 Causes Skin Irritation When Applied as a Topical Gel in Healthy Participants
- Conditions
- Interventions
- First Posted Date
- 2024-07-22
- Last Posted Date
- 2024-08-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 40
- Registration Number
- NCT06511973
- Locations
- 🇺🇸
TKL Research, Inc., Fair Lawn, New Jersey, United States
An Observational Study to Learn More About the Use of Darolutamide as a Part of a Combination Therapy in Belgian Men With Metastatic Hormone-Sensitive Prostate Cancer in Routine Medical Care
- First Posted Date
- 2024-07-12
- Last Posted Date
- 2024-10-24
- Lead Sponsor
- Bayer
- Target Recruit Count
- 106
- Registration Number
- NCT06498921
- Locations
- 🇧🇪
Many locations, Multiple Locations, Belgium
A Study to Understand the Usage of an Artificial Intelligence Technology Called DARWEN for Eye Disorders and to Find Out the Factors Influencing Treatment Frequencies in People With nAMD and RVO
- Conditions
- Interventions
- First Posted Date
- 2024-07-10
- Last Posted Date
- 2024-07-10
- Lead Sponsor
- Bayer
- Target Recruit Count
- 1350
- Registration Number
- NCT06495203
- Locations
- 🇨🇦
Bayer, Mississauga, Canada
An Observational Study Called ROVER to Learn More About How Well Vericiguat Works in People Who Were Newly Treated With Vericiguat in Routine Medical Care in Germany
- Conditions
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-11-22
- Lead Sponsor
- Bayer
- Target Recruit Count
- 500
- Registration Number
- NCT06486844
- Locations
- 🇩🇪
Bayer, Wuppertal, Germany
A Study to Learn How Safe BAY3283142 is When Taken as a Single Dose or as Multiple Doses in Healthy Chinese Participants
- Conditions
- Interventions
- First Posted Date
- 2024-07-05
- Last Posted Date
- 2024-08-23
- Lead Sponsor
- Bayer
- Target Recruit Count
- 23
- Registration Number
- NCT06487845
- Locations
- 🇨🇳
The First Affiliated Hospital of Guangzhou University of TCM, Guangzhou, Guangdong, China
A Study to Learn About the Taste of Vericiguat Given in Liquid Form in Healthy Male Participants Aged 18 to 45 Years
- Conditions
- Interventions
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-10-07
- Lead Sponsor
- Bayer
- Target Recruit Count
- 19
- Registration Number
- NCT06474208
- Locations
- 🇩🇪
Clinical Research Services | Clinical Research Services Mannheim - Phase one unit, Mannheim, Baden-Württemberg, Germany
A Study to Learn More About How Well BAY 2927088 Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations in the Genes of Human Epidermal Growth Factor Receptor 2 (HER2)
- Conditions
- Interventions
- First Posted Date
- 2024-06-11
- Last Posted Date
- 2024-11-15
- Lead Sponsor
- Bayer
- Target Recruit Count
- 278
- Registration Number
- NCT06452277
- Locations
- 🇨🇳
Fujian Cancer Hospital, Fuzhou, Fujian, China
🇨🇳Hunan Cancer Hospital, Changsha, Hunan, China
🇨🇳Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China
A Study to Learn About the Safety of BAY3283142 in People With Mild to Moderate High Blood Pressure
- Conditions
- Interventions
- First Posted Date
- 2024-05-24
- Last Posted Date
- 2024-12-16
- Lead Sponsor
- Bayer
- Target Recruit Count
- 72
- Registration Number
- NCT06428825
- Locations
- 🇩🇪
Clinical Research Services | Clinical Research Services Mannheim - Phase one unit, Mannheim, Baden-Württemberg, Germany
🇩🇪CRS Clinical Research Services Berlin GmbH, Berlin, Germany
A Study to Learn More About How Well 8 Milligram Aflibercept Works and How Safe it is in Chinese Participants With Diabetic Macular Edema
- Conditions
- Interventions
- First Posted Date
- 2024-05-21
- Last Posted Date
- 2024-12-19
- Lead Sponsor
- Bayer
- Target Recruit Count
- 322
- Registration Number
- NCT06422507
- Locations
- 🇨🇳
Shanghai Jiao Tong University School of Medicine (SJTUSM) - XinHua Hospital, Shanghai, China
🇨🇳Eye & Ent Hospital of Fudan University, Shanghai, China
🇨🇳Joint Shantou International Eye Center (JSIEC)Shantou University & the Chinese University of Hong Kong, Shantou, China